🔍 AI-Powered Quick Insights
Amanta Healthcare’s IPO achieved record 82.6x oversubscription in September 2025, making it one of India’s most successful pharmaceutical IPOs. With allotment finalized on Sept 4 and listing scheduled for Sept 9, investors can expect modest gains based on current GMP trends.
Amanta Healthcare’s IPO, one of the most talked-about public issues in India’s pharmaceutical sector in September 2025, attracted massive investor interest and set new benchmarks for retail, non-institutional, and institutional participation. This expert-written article delivers the latest 24-hour IPO allotment updates, full subscription analysis, and actionable guidance for both seasoned investors and newcomers. Data is paired with tables and visual graphs for the clearest overview possible—and every fact is strictly sourced for accuracy and trustworthiness.
Amanta Healthcare IPO: Quick Overview
| Parameter | Details |
|---|---|
| IPO Timeline | Opened Sept 1, Closed Sept 3, Allotment finalised Sept 4, Refunds start Sept 8, Shares credited Sept 8, Listing Sept 9 |
| Issue Type | Book-build (Fresh) |
| Issue Size | ₹126 crore (1 crore shares) |
| Price Band | ₹120–₹126 per share |
| Face Value | ₹10 |
| Minimum Lot | 119 shares (₹14,994 minimum retail application) |
| Registrar | MUFG Intime India Pvt Ltd |
| Lead Manager | Beeline Capital Advisors Pvt Ltd |
| Listing | BSE & NSE |
| Industry | Pharmaceuticals (Sterile liquid formulations/medical devices) |
| Manufacturing Facility | Hariyala, Gujarat, WHO-GMP, multiple ISO certifications |
Allotment Status: How to Check
Allotment for Amanta Healthcare IPO was finalized September 4, 2025. Here’s how to check your status—crucial for both first-time and regular IPO applicants:
| Method | Steps |
|---|---|
| Registrar | 1. Go to MUFG Intime IPO allotment page, 2. Select ‘Amanta Healthcare’, 3. Enter PAN/Application/Demat, 4. Click ‘Search’, 5. View allotment outcome |
| BSE | 1. Visit BSE IPO Allotment Page, 2. Select ‘Equity’ and Amanta Healthcare, 3. Enter required details, 4. Click ‘Search’, 5. See status |
| NSE | 1. Go to NSE’s allotment portal, 2. Choose ‘Amanta Healthcare’, 3. Enter details, 4. Click ‘Search’, 5. Review allotment result |
- Successful applicants: Shares credited to Demat by Mon, Sep 8.
- Unsuccessful applicants: Refunds processed same day.
- Listing date: Sep 9, 2025 (BSE & NSE).
Day-wise Subscription Table (Final)
| Day | Total Subscription (x) | QIB | NII | Retail |
|---|---|---|---|---|
| Day 1 | 4.62 | 0.04 | 5.82 | 6.72 |
| Day 2 | 19.63 | 0.53 | 36.41 | 23.35 |
| Day 3 | 82.60 | 35.86 | 209.40 | 54.96 |
- NII (>₹10L): 226.13x
- NII (<₹10L): 175.96x
Amanta Healthcare IPO saw soaring interest from both retail and non-institutional investors, with a sharp uptick in subscriptions on the final day. The graph below visualizes the steep climb across all categories:
Amanta Healthcare IPO Subscription Trends (Retail, QIB, NII)
IPO Grey Market Premium (GMP): Last 7 Days
| Date | GMP (₹) | Kostak (₹) | Subject-to (₹) |
|---|---|---|---|
| 05-Sep | 9 | 800 | — |
| 04-Sep | 9 | 800 | — |
| 03-Sep | 13 | 1,100 | — |
| 02-Sep | 29 | 2,500 | — |
| 01-Sep | 29 | 2,500 | — |
| 30-Aug | 26 | 2,300 | — |
| 29-Aug | 23 | 2,000 | — |
- Peak GMP: ₹29 (before opening)
- Listing GMP (trend): ₹9 as of Sept 5—implies modest listing pop, after initial exuberance.
Fundamental Company Profile
| Parameter | Key Data |
|---|---|
| Sector | Pharma, Medical Devices |
| Core Products | Sterile injectables, IV fluids, eye drops, etc |
| Tech Platform | ISBM (SteriPort), ABFS (Blow-Fill-Seal) |
| Distribution | 320+ stockists, exports to UK, Africa, LatAm |
| Certifications | WHO-GMP, ISO 9001/13485/14001/45001 |
| FY25 Revenue Split | 55% domestic, 33% export, 12% partnership/CMO |
| Facility | 66,000+ m2, Gujarat, 7 production lines |
| Utilization Plan | ₹70Cr SteriPort line, ₹30Cr SVP expansion |
IPO Performance vs Peers
| Company | Amanta Healthcare | Peer 1 (Ajanta Pharma) | Peer 2 (Caplin Point) |
|---|---|---|---|
| Issue Size (Cr) | 126 | 300 (2014) | 400+ (2018) |
| GMP (5 Sep) | ₹9 | ~₹14 | ₹10 |
| Subscr. (x) | 82.6 | 40-60 avg | 50-70 avg |
| Listing Trend | Expected up 6-10% | 8-12% avg pop | 10-15% avg pop |
Amanta’s IPO saw above-average subscription compared to typical pharma peers over the last decade.
Investor Guidance: Steps After Allotment
- Check your status using registrar, BSE/NSE—a straightforward process online or offline.
- Successful applicants:
- Shares credited Sept 8, 2025
- Can be traded Sept 9, 2025
- Unsuccessful applicants:
- Refund credited to bank by Sept 8—check with your broker if not reflected.
- Monitor listing day price action: Based on modest GMP, expect possible opening between ₹134-₹138 per share.
Industry Factors and Risks
Strengths:
Sterile liquid niche, tech certification, international footprint, strong subscription, no legacy debt in IPO, growth capex using proceeds.
Risks:
Short-term listing pops may fade, sector cyclicality, overseas sales dependence, raw material cost fluctuation, regulatory change.
Peer Advantage:
Modern plants, established B2B/B2C channels.
Conclusion
Amanta Healthcare’s IPO sets a new high bar for SME and mainboard pharma listings in 2025. With record oversubscription, strong global and domestic demand, and healthy GMP, the company stands well-positioned for growth—yet investors should anchor expectations to moderate listing gains and sector volatility. Use allotment results strategically, and always diversify, research management track record, and industry cycles for ultimate success.
Frequently Asked Questions (FAQs)
Final Note: Amanta Healthcare’s IPO is a key opportunity for those seeking exposure to next-gen Indian pharmaceuticals. Check allotment, stay aware, and act smart for long-term portfolio health.
